Patent details
301190
Product Name:
Een combinatie van rilpivirine of een door het basisoctrooi beschermde therapeutisch equivalente vorm daarvan, zoals een farmaceutisch aanvaardbaar additiezout van rilpivirine, met inbegrip van het hydrochloride-zout van rilpivirine, en emtricitabine.
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301190
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP3808743
Status:
Application Pending
Application number:
301190
Procedural language:
Dutch
First Applicant Residence Country:
Belgium (BE)
Marketing Authorization
Marketing Authorization Number:
EU/1/11/737/001-002
Marketing Authorization Type:
EEA
Marketing Authorization Date:
28/11/2011
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
29/07/2022
First Marketing Authorization date:
28/11/2011
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
29/07/2022
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
29/07/2022
Name:
Janssen Pharmaceutica NV
Address:
Turnhoutseweg 30, 2340 Beerse, Belgium (BE)
Agent
Name:
ir. F.A. Geurts c.s.
From:
29/07/2022
Address:
Octrooibureau Vriesendorp & Gaade B.V.
Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
Bulletin Heading:
SPC
Journal edition number:
31/22
Publication date:
03/08/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
17/10/2022
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/3/8/5/0/1/0800810583/docs/301190_8_incomingcorrespondencepaper20221017022253344.pdf
04/08/2022
Outgoing Correspondence
Letter to applicant
3
PDF
/3/8/5/0/1/0800810583/docs/301190_0_496688l173.pdf
01/08/2022
Outgoing Correspondence
Confirmation receipt request
1
PDF
/3/8/5/0/1/0800810583/docs/301190_1_496304l174.pdf
29/07/2022
Application Form
First filed application form
4
PDF
/3/8/5/0/1/0800810583/docs/301190_2_applicationform20220729043142882.pdf
29/07/2022
SPC Documents
Marketing Authorization SPC
4
PDF
/3/8/5/0/1/0800810583/docs/301190_3_supplprotectioncertificate20220729043240753.pdf
29/07/2022
SPC Documents
Summary of the characteristics of the product
33
PDF
/3/8/5/0/1/0800810583/docs/301190_4_supplprotectioncertificate20220729043357806.pdf
29/07/2022
SPC Documents
Annex SPC
1
PDF
/3/8/5/0/1/0800810583/docs/301190_5_supplprotectioncertificate20220729043433352.pdf
29/07/2022
SPC Documents
Accompanying letter SPC
3
PDF
/3/8/5/0/1/0800810583/docs/301190_6_supplprotectioncertificate20220729043614682.pdf
29/07/2022
SPC Documents
Annex SPC
10
PDF
/3/8/5/0/1/0800810583/docs/301190_7_supplprotectioncertificate20220729043521950.pdf